Idorsia Valuation

Is IDIA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IDIA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IDIA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IDIA's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for IDIA?

Other financial metrics that can be useful for relative valuation.

IDIA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue10.4x
Enterprise Value/EBITDA-3.9x
PEG Ratio-0.5x

Price to Earnings Ratio vs Peers

How does IDIA's PE Ratio compare to its peers?

The above table shows the PE ratio for IDIA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average17.1x
SANN Santhera Pharmaceuticals Holding
2x32.5%CHF 108.1m
XLS Xlife Sciences
10.3xn/aCHF 152.7m
VYGR Voyager Therapeutics
37x-24.1%US$334.3m
COPN Cosmo Pharmaceuticals
19.2x-3.3%CHF 1.2b
IDIA Idorsia
11x-20.4%CHF 315.3m

Price-To-Earnings vs Peers: IDIA is good value based on its Price-To-Earnings Ratio (11x) compared to the peer average (17.1x).


Price to Earnings Ratio vs Industry

How does IDIA's PE Ratio compare vs other companies in the European Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a35.8%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a35.8%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: IDIA is good value based on its Price-To-Earnings Ratio (11x) compared to the European Biotechs industry average (26.4x).


Price to Earnings Ratio vs Fair Ratio

What is IDIA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IDIA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11x
Fair PE Ratio11.6x

Price-To-Earnings vs Fair Ratio: IDIA is good value based on its Price-To-Earnings Ratio (11x) compared to the estimated Fair Price-To-Earnings Ratio (11.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IDIA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 1.75
CHF 1.78
+1.7%
31.9%CHF 2.60CHF 1.00n/a5
Sep ’25CHF 2.14
CHF 1.78
-16.9%
31.9%CHF 2.60CHF 1.00n/a5
Aug ’25CHF 2.55
CHF 1.76
-31.2%
29.6%CHF 2.60CHF 1.00n/a6
Jul ’25CHF 2.10
CHF 1.69
-19.4%
31.1%CHF 2.60CHF 1.00n/a8
Jun ’25CHF 2.59
CHF 1.69
-34.8%
31.1%CHF 2.60CHF 1.00n/a8
May ’25CHF 1.81
CHF 1.72
-4.8%
32.0%CHF 2.60CHF 1.00n/a8
Apr ’25CHF 2.83
CHF 2.10
-25.8%
41.1%CHF 4.00CHF 1.00n/a8
Mar ’25CHF 1.99
CHF 2.07
+3.8%
41.7%CHF 4.00CHF 1.00n/a8
Feb ’25CHF 1.47
CHF 2.07
+40.9%
41.7%CHF 4.00CHF 1.00n/a8
Jan ’25CHF 2.11
CHF 2.07
-2.2%
41.7%CHF 4.00CHF 1.00n/a8
Dec ’24CHF 2.18
CHF 2.63
+20.6%
64.5%CHF 6.50CHF 1.00n/a8
Nov ’24CHF 1.70
CHF 4.24
+149.0%
79.2%CHF 12.00CHF 1.00n/a8
Oct ’24CHF 2.59
CHF 6.38
+146.1%
36.3%CHF 12.00CHF 4.00n/a8
Sep ’24CHF 5.24
CHF 6.28
+19.9%
35.1%CHF 12.00CHF 4.00CHF 2.149
Aug ’24CHF 6.90
CHF 5.79
-16.1%
13.1%CHF 6.50CHF 4.20CHF 2.557
Jul ’24CHF 6.45
CHF 10.91
+69.1%
62.8%CHF 30.00CHF 6.00CHF 2.1010
Jun ’24CHF 7.99
CHF 13.72
+71.8%
57.0%CHF 30.00CHF 7.00CHF 2.599
May ’24CHF 8.59
CHF 13.46
+56.7%
56.6%CHF 30.00CHF 6.00CHF 1.8110
Apr ’24CHF 10.02
CHF 15.23
+52.0%
39.7%CHF 30.00CHF 9.00CHF 2.8311
Mar ’24CHF 12.70
CHF 15.23
+20.0%
39.7%CHF 30.00CHF 9.00CHF 1.9911
Feb ’24CHF 15.18
CHF 17.43
+14.8%
39.2%CHF 36.00CHF 10.00CHF 1.4711
Jan ’24CHF 13.42
CHF 18.17
+35.4%
39.1%CHF 36.00CHF 10.00CHF 2.1111
Dec ’23CHF 14.36
CHF 19.65
+36.9%
35.0%CHF 36.00CHF 10.00CHF 2.1811
Nov ’23CHF 16.23
CHF 19.71
+21.4%
34.8%CHF 36.00CHF 10.00CHF 1.7010
Oct ’23CHF 12.86
CHF 22.91
+78.2%
33.2%CHF 36.00CHF 10.00CHF 2.5910
Sep ’23CHF 14.36
CHF 24.92
+73.6%
25.4%CHF 36.00CHF 15.00CHF 5.2411

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies